CRISPR Therapeutics AGCRSPNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -82.50% | +71.63% | -100.00% | +0.00% | -97.53% |
| Gross Profit Growth | -80.56% | +0.00% | +0.00% | +0.00% | -267.14% |
| EBITDA Growth | -180.21% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | -192.82% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | -141.76% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | -139.29% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | -140.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +7.25% | +5.07% | +2.53% | +7.12% | +5.22% |
| Weighted Average Shares Diluted Growth | +5.09% | +5.07% | +2.53% | +7.12% | +5.22% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | -149.15% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | -149.67% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -87.50% | +0.00% | +0.00% | +0.00% | -100.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +0.56% | -11.19% | -13.25% | -0.48% | +1.04% |
| Book Value per Share Growth | -4.32% | -16.46% | -15.75% | -7.79% | -5.47% |
| Debt Growth | -6.26% | -6.63% | -6.85% | +77.46% | +76.54% |
| R&D Expense Growth | -13.65% | +1.61% | +120.59% | -28.31% | -5.22% |
| SG&A Expenses Growth | +9.98% | +7.48% | -2.90% | -2.80% | +1.52% |